Available in both TIRZ GLP-2 10mg and TIRZ GLP-2 30mg strengths, this peptide is manufactured to strict quality standards for professional laboratory research applications
your provider may adjust based on tolerance and clinical response
Chronic Weight Management : Mounjaro is also licensed for weight management in adults with a body mass index (BMI) of 30 kg/m (obesity) or 27 kg/m (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease
Direct answer: Common side effects include nausea, constipation, diarrhea, bloating, and reduced appetite
This active comparator design was selected to ensure that all patients had similar motivations for weight management and shared comparable baseline characteristics, thus allowing for a more accurate comparison of outcomes
Standard dose escalation The typical tirzepatide dose escalation schedule progresses as follows: Weeks 1-4: 2.5mg once weekly Weeks 5-8: 5.0mg once weekly Weeks 9-12: 7.5mg once weekly Weeks 13-16: 10.0mg once weekly Weeks 17-20: 12.5mg once weekly Weeks 21+: 15.0mg once weekly (maximum dose) This gradual escalation allows the body to adapt to each dose level, minimizing gastrointestinal side effects that commonly occur when starting or increasing the dose
